Wrapping Things Up With Some Odds and Ends
It seemed like the indexes were largely stuck for most of the trading day following the July CPI reading that was very anticipated, but elicited little reaction as it came in as expected. The Nasdaq was flat, the S&P 500 was barely positive while the Dow tacked on more than 200 points.
The rotation into small-caps that was a huge theme in July has largely reversed in August. The Russell 2000 was down 0.5% Wednesday and has lost some 8% so far this month.
Some odds and ends to finish out the day:
-- Israel-headquartered Teva Pharmaceutical TEVA hit a five-year high today despite continued tensions in the Middle East.
-- Moody's is in a generous mood today as it revised the State of New Jersey's outlook to positive from stable. It also upgraded the debt ratings on regional bank KeyCorp KEY earlier today. I don’t think regional banks have seen the worse from the CRE implosion, and I expect to continue to see myriad license plates from new emigres from the Garden State down here in Delray Beach for what it is worth.
-- Gilead Sciences GILD, a covered call trade idea of mine from a few months ago, continues on its recent roll. Today it announced that the FDA approved its liver disease therapy Livdelzi (seladelpar). Gilead picked up this new asset with its recent acquisition of of CymaBay Therapeutics CBAY.
As always, it was fun standing in for Doug Kass on the Daily Diary despite a lackluster day in the markets. Until next time.
BY Bret Jensen · Aug 14, 2024, 4:30 PM EDT